ONCO.NASDAQOnconetix, INC
10-Q: Onconetix Q3: Revenue Plunges, Debt Restructured, Going Concern
Sentiment:
Quarterly Report
Onconetix, Inc. reported a significant revenue decline and continued operating losses in its Q3 2025 filing, despite recent capital raises and debt restructuring, raising substantial doubt about its ability to continue as a going concern.
Delay expectedThe company repeatedly extended the maturity dates for the Veru Notes Payable (April Veru Note and September Veru Note) multiple times throughout 2024 and 2025, indicating difficulties in meeting original payment obligations.The related party debenture's maturity date was extended from June 30, 2024, to October 31, 2024.
Capital raiseSeries D PIPE Financing: Completed on September 22, 2025, with eleven institutional investors, raising approximately $12.9 million (aggregate purchase price) and $9.3 million in net cash proceeds through the issuance of Series D convertible preferred stock and warrants.Series E PIPE Financing: Completed on October 1, 2025 (subsequent event), with institutional investor(s), raising approximately $6.25 million in net cash proceeds through the issuance of Series E convertible preferred stock and warrants.Equity Line of Credit (ELOC): The company may sell up to $25.0 million of common stock, with approximately $17.9 million remaining available. However, management determined that the funds readily available under the ELOC will not be sufficient to raise substantial additional capital for continuing operations.Management explicitly states plans to pursue additional equity or debt financing to support operations and strategic initiatives, as current cash is insufficient for the next 12 months.
Worse than expectedRevenue for the nine months ended September 30, 2025, decreased by 71.8% compared to the same period in 2024.The company continues to report substantial operating losses and has a significant working capital deficit and accumulated deficit.The explicit "substantial doubt about the Company's ability to continue as a going concern" indicates a critical financial situation.The abandonment of the ENTADFI product, after significant investment, represents a failed commercialization effort.The company incurred substantial losses on debt extinguishment and preferred stock issuance.
Summary
- Net loss for the nine months ended September 30, 2025, was $19.7 million, an improvement from $29.3 million in the same period of 2024.
- Revenue for the nine months ended September 30, 2025, decreased by 71.8% to $0.5 million from $1.8 million in 2024, primarily due to a shift from development services and product sales to license revenue.
- Cash balance as of September 30, 2025, was $0.8 million, increasing to $6.1 million by November 10, 2025, following recent financings.
- The company has a working capital deficit of $15.0 million and an accumulated deficit of $136.9 million as of September 30, 2025.
- Substantial doubt exists about the company's ability to continue as a going concern for the next year.
- The company abandoned commercialization of ENTADFI and is focusing on Proclarix.
- A Series D PIPE Financing in September 2025 raised $9.3 million in net cash proceeds and settled approximately $8.8 million in Veru notes payable.
- A subsequent Series E PIPE Financing in October 2025 raised $6.25 million in net cash proceeds.
- The Ocuvex merger agreement was terminated, with Onconetix paying a $302,343.55 termination fee.
- Identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties, ineffective risk assessment, and insufficient accounting resources.
Sentiment
Score: 2
Explanation: The company faces severe financial distress, evidenced by a 'going concern' warning, significant accumulated deficit, and declining revenue. While recent capital raises provide temporary relief and cost-cutting measures are in place, the fundamental business model struggles, and internal control weaknesses add to the risk profile. The abandonment of a previously acquired product (ENTADFI) further underscores operational challenges.
Positives
- Net loss for the nine months ended September 30, 2025, improved to $19.7 million from $29.3 million in the prior year.
- Selling, general and administrative expenses decreased by $3.1 million (35.6%) for the nine months ended September 30, 2025, due to cost reduction efforts.
- Successful Series D PIPE Financing in September 2025 generated $9.3 million in net cash proceeds.
- Successful Series E PIPE Financing in October 2025 (subsequent event) generated $6.25 million in net cash proceeds.
- Settlement of approximately $8.8 million in Veru notes payable through the Series D financing, reducing significant debt obligations.
- Gain on forgiveness of accounts payable of $0.9 million for the nine months ended September 30, 2025.
- Full termination and settlement of the defined benefit pension plan as of September 30, 2025, reducing future obligations.
- Secured a license agreement with Immunovia AB for the PancreaSure test, including an upfront payment of $300,000 and future royalties.
Negatives
- Substantial doubt about the company's ability to continue as a going concern within one year.
- Revenue for the nine months ended September 30, 2025, decreased significantly by 71.8% to $0.5 million from $1.8 million in the prior year.
- Working capital deficit of $15.0 million and an accumulated deficit of $136.9 million as of September 30, 2025.
- Cash used in operating activities was $6.6 million for the nine months ended September 30, 2025.
- Abandonment of ENTADFI commercialization and destruction of its inventory, indicating a failed product strategy.
- Incurred a $5.4 million loss on extinguishment of notes payable and a $2.5 million loss on issuance of preferred stock and warrants for the nine months ended September 30, 2025.
- Termination of the Ocuvex merger agreement resulted in a $302,343.55 termination payment.
- Identified material weaknesses in internal control over financial reporting, indicating significant control deficiencies.
- Goodwill impairment of $11.5 million for the nine months ended September 30, 2025.
- Reliance on single-source suppliers for Proclarix manufacturing.
Risks
- Incurred significant net losses since inception and anticipates continued substantial net losses, potentially never achieving profitability.
- Substantial doubt about the ability to continue as a going concern, requiring significant additional funding.
- Inability to raise additional capital when needed could force delays, reductions, or termination of product development or other operations.
- Current liabilities are significant ($16.3 million as of September 30, 2025), and inability to pay if creditors demand immediate payment could lead to bankruptcy.
- Reliance on third parties (e.g., LabCorp) for development, marketing, distribution, and sales of Proclarix.
- Reliance on third parties, including manufacturers and logistics companies, with main suppliers being single-source.
- Potential for product liability lawsuits and associated costs, which could limit commercialization.
- Competition from other therapies or diagnostics.
- Inability to obtain and maintain intellectual property protection or incur substantial costs from intellectual property lawsuits.
- Disruptions in the business of the Company or Proteomedix could adversely affect financial results.
- Material weaknesses in internal control over financial reporting could lead to undetected misstatements.
Future Outlook
Management anticipates continued significant operating losses for the foreseeable future as the company focuses on commercializing Proclarix. Future funding requirements are substantial, and the company intends to pursue additional equity or debt financing, as current cash balances are not sufficient to fund operations over the next twelve months. There is no assurance that additional funding will be available on favorable terms, if at all, which may necessitate curtailing development and commercialization efforts or further expense reductions.
Management Comments
- Our operating activities to date have been devoted to seeking licenses, engaging in research and development activities, potential asset and business acquisitions, expenditures associated with the previously planned commercial launch of ENTADFI, and the commercialization of Proclarix.
- The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future.
- While these capital raises may enable the Company to sustain current operations and meet existing obligations, the Company continues to generate recurring net operating losses and has not yet established sustained positive cash flows to support its strategic growth initiatives, which includes the commercialization of Proclarix, and the development and commercialization of the Companys future product candidates.
- These factors raise substantial doubt about the Companys ability to continue as a going concern within one year from the date of the issuance of these condensed consolidated financial statements.
- Managements plans for funding the Companys operations include generating product revenue from sales of Proclarix, which is still subject to further successful development and commercialization activities within certain jurisdictions. Management also intends to pursue additional equity or debt financing to support operations and strategic initiatives.
- If additional capital is not secured, the Company may need to curtail clinical trials, development, and commercialization efforts, and take further measures to reduce expenses to conserve cash.
- We are currently focusing our efforts on commercializing Proclarix.
- We do not anticipate incurring significant research and development expenses in the near future, unless we are able to resume such activities.
Industry Context
Onconetix operates in the highly competitive and capital-intensive biotechnology sector, specifically targeting mens health and oncology diagnostics with Proclarix. The abandonment of ENTADFI highlights the challenges of commercializing new pharmaceutical products, while the focus on Proclarix positions the company in the growing market for advanced cancer diagnostics. The reliance on partnerships like LabCorp for U.S. commercialization is a common strategy for smaller biotech firms to leverage established distribution networks, but also introduces dependency risks. The significant capital raises and ongoing 'going concern' warning are typical for early-stage commercial biotech companies that require substantial investment before achieving sustained profitability.
Comparison to Industry Standards
- The company's shift from vaccine development to commercial-stage diagnostics (Proclarix) and the abandonment of ENTADFI reflect a common industry trend where companies pivot strategies based on market viability and financial constraints.
- The licensing agreement with LabCorp for Proclarix in the U.S. is a standard model for smaller diagnostic companies to gain market access without building extensive internal sales and marketing infrastructure, similar to how many diagnostic startups partner with larger clinical lab networks.
- The repeated reverse stock splits (1:40 in Sep 2024, 1:85 in June 2025) are often indicative of a company struggling to maintain its stock price above minimum exchange requirements, a situation seen in many small-cap biotech firms facing significant losses and dilution.
- The ongoing "going concern" warning and continuous need for capital raises (Series D, Series E, ELOC) are typical for pre-revenue or early-revenue biotech companies, but the magnitude of the accumulated deficit ($136.9 million) and working capital deficit ($15.0 million) suggests a more challenging financial position compared to peers with clearer paths to profitability or stronger balance sheets.
- The identified material weaknesses in internal controls are a red flag, often seen in rapidly evolving or under-resourced smaller companies, and are below the standards expected for publicly traded entities.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Interim Chief Executive Officer and Interim Chief Financial Officer | NA | Karina M. Fedasz | NA | Current role as of filing date. |
| Board Member | NA | Thomas Meier, PhD | 2024-02-06 | Appointment to the board. |
| Employees involved with ENTADFI program | NA | NA | 2024-04-30 | Termination as part of cost reduction efforts and initial pause in commercializing ENTADFI. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reverse Stock Split | Effected a reverse stock split of all issued and outstanding Common Stock at a ratio of one-for-eighty-five (1:85). | 2025-06-13 | Retrospective adjustment of common stock, warrants, and share-based awards exercise prices and per share data. Did not adjust authorized shares or par value. |
| Internal Control Weaknesses | Identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties, ineffective risk assessment, insufficient accounting resources, and IT control deficiencies. | 2025-09-30 | Could lead to material misstatements not being prevented or detected. Remediation plan is in progress to improve controls. |
| Board Authorization | Board of Directors authorized the creation of Series C Convertible Preferred Stock. | 2024-10-01 | Enabled subsequent capital raises through preferred stock issuance. |
| Board Authorization | Board approved a stock repurchase program (later terminated). | 2022-11-10 | Initially allowed for share repurchases, but termination indicates a shift in capital allocation strategy or financial constraints. |
| Board Termination | Board terminated the stock repurchase program. | 2024-11-13 | Eliminated the ability to repurchase shares, likely due to financial constraints. |
Legal Proceedings
- Not currently subject to any material legal proceedings, nor is any material legal proceeding threatened against the company or its officers/directors in their corporate capacity.
Related Party Transactions
- Subscription Agreement with PMX Investor (a 5% stockholder) for the sale of units, including a make-whole provision. The related party debenture of $5.0 million was issued to the PMX Investor and later settled through the issuance of shares.
- Consulting agreement with a firm affiliated with Dr. Thomas Meier (a board member) for success fees and expense reimbursement. Dr. Meier is entitled to 10% of success fees earned by the affiliated firm.
Stakeholder Impact
- Shareholders: Significant dilution from recent capital raises (Series D, Series E, ELOC) and preferred stock conversions. The "going concern" warning poses a substantial risk to investment value. Repeated reverse stock splits indicate severe share price pressure.
- Employees: Termination of three employees involved with the ENTADFI program as part of cost reduction efforts. Pension plan fully terminated and settled.
- Customers: Abandonment of ENTADFI means existing customers for that product will no longer be served. Focus on Proclarix aims to serve new customers in prostate cancer diagnostics.
- Suppliers: Reliance on single-source suppliers for Proclarix manufacturing creates dependency and potential supply chain risks.
- Creditors: Debt restructuring and settlement of Veru notes reduced immediate obligations, but significant current liabilities ($16.3 million) remain, posing a risk if immediate payment is demanded.
Next Steps
- Commercialize Proclarix, including further successful development and commercialization activities within certain jurisdictions.
- Pursue additional equity or debt financing to support operations and strategic initiatives.
- Implement remediation plan for identified material weaknesses in internal control over financial reporting.
- Destroy inventory of ENTADFI product.
- Immunovia AB to make a second payment of $300,000 by March 31, 2026, and begin royalty payments from January 1, 2026.
- LabCorp to commence sales of Licensed Products under the license agreement.
Key Dates
| Date | Description |
|---|---|
| 2018-10-26 | Company (Onconetix, Inc.) was formed. |
| 2022-11-10 | Board approved stock repurchase program (terminated Nov 13, 2024). |
| 2022-11-18 | Board approved increase to maximum price for stock repurchase program. |
| 2023-03-23 | Proteomedix entered into a license agreement with LabCorp for Proclarix in the United States. |
| 2023-04-21 | Company changed its corporate name from Blue Water Vaccines Inc. to Blue Water Biotech, Inc. |
| 2023-04-24 | Company filed an amendment to its Amended and Restated Certificate of Incorporation. |
| 2023-05-09 | Board's Compensation Committee approved issuance of restricted stock to executive officers, employees, and consultants. |
| 2023-05-31 | Board's Compensation Committee approved issuance of 7 shares of restricted stock to non-executive Board members, vesting May 31, 2024. |
| 2023-07-21 | Company entered into a Licensing and Services Master Agreement with a vendor for commercialization services (terminated Oct 12, 2023). |
| 2023-07-29 | Second statement of work entered with the same vendor for subscription services (term through July 14, 2025). |
| 2023-10-01 | Board of Directors authorized the creation of Series C Convertible Preferred Stock. |
| 2023-10-02 | Company entered into Series C Securities Purchase Agreement and ELOC Purchase Agreement. |
| 2023-10-03 | Company issued 3,000 shares of Series A Convertible Preferred Stock in exchange for settlement of $3.0 million in notes payable to Veru, Inc. |
| 2023-10-12 | Company terminated the Master Services Agreement and statements of work with the vendor. |
| 2023-12-15 | Onconetix acquired 100% of Proteomedix AG; Company changed its corporate name from Blue Water Biotech, Inc. to Onconetix, Inc.; Company filed a Certificate of Designations for Series B Convertible Preferred Stock and issued 2,696,729 shares. |
| 2023-12-18 | Company entered into a subscription agreement with the PMX Investor. |
| 2024-01-04 | Consulting agreement with a firm affiliated with Dr. Thomas Meier became effective. |
| 2024-01-23 | Company issued a non-convertible debenture of $5.0 million to the PMX Investor; Subscription Agreement amended to include interest provision for the debenture. |
| 2024-02-06 | Thomas Meier, PhD, appointed as a member of the Company's board of directors. |
| 2024-02-14 | Company issued 1 share of restricted stock to a non-executive Board member, vesting June 14, 2024. |
| 2024-04-01 | Proteomedix office and lab lease amended to add additional space. |
| 2024-04-16 | Proteomedix board approved a two-year extension of 144 vested stock options. |
| 2024-04-19 | Maturity date of April Veru Note. |
| 2024-04-24 | Company entered into a forbearance agreement with Veru; Maturity date of related party debenture extended to October 31, 2024. |
| 2024-04-25 | $50,000 of principal due under April Veru Note paid. |
| 2024-04-30 | Termination of three employees involved with the ENTADFI program, effective date. |
| 2024-06-30 | ENTADFI assets fully impaired. |
| 2024-09-05 | Stockholder approval obtained for Series B Preferred Stock conversion. |
| 2024-09-19 | Company entered into an Amended and Restated Forbearance Agreement with Veru. |
| 2024-09-24 | Company effected a reverse stock split (1:40); Veru converted all 3,000 shares of Series A Convertible Preferred Stock into 1,679 common shares; Company effected conversion of all 2,696,729 shares of Series B Preferred Stock into 79,315 common shares; Company converted all unpaid principal and accrued interest under the Debenture into 513,424 common shares and 154,027 pre-funded warrants. |
| 2024-09-26 | Company issued 195 restricted stock to Board members, vesting August 31, 2025. |
| 2024-09-30 | Maturity date of September Veru Note. |
| 2024-10-01 | Interest accrual at 10% per annum on unpaid principal balance of September Veru Note commenced. |
| 2024-10-20 | Increased payment percentage to Veru (25% of Ordinary Cash Revenue) began for cash receipts in September 2024. |
| 2024-10-31 | Extended maturity date of related party debenture. |
| 2024-11-13 | Board terminated the stock repurchase program. |
| 2024-11-26 | Company entered into another Amended and Restated Forbearance Agreement with Veru. |
| 2024-12-31 | If Veru Notes repaid in cash by this date, September Veru Note principal reduced to $3.5 million. |
| 2025-02-12 | Company issued a subordinated promissory note to Keystone Capital Partners, LLC, maturing November 12, 2025. |
| 2025-02-16 | Maturity date of May Keystone Note. |
| 2025-02-24 | Company issued 20 shares of restricted stock to an executive Board member, vesting August 31, 2025. |
| 2025-03-05 | Maturity date of June Keystone Note. |
| 2025-03-31 | April 2024 Forbearance Period end date; Second payment of $300,000 from Immunovia AB due. |
| 2025-03-31 | Veru and Company entered into a waiver agreement, extending April Veru Note payment to April 14, 2025. |
| 2025-04-14 | Extended payment date for April Veru Note. |
| 2025-04-23 | Veru and Company entered into a limited waiver agreement, extending April Veru Note payment to June 30, 2025. |
| 2025-05-16 | Company issued a subordinated promissory note to Keystone Capital Partners, LLC, maturing February 16, 2026. |
| 2025-05-28 | Maturity date of August 28 Keystone Notes. |
| 2025-06-05 | Company issued a subordinated promissory note to Keystone Capital Partners, LLC, maturing March 5, 2026. |
| 2025-06-13 | Company effected a reverse stock split (1:85). |
| 2025-06-17 | Company entered into a separate consulting agreement with a firm affiliated with Dr. Meier. |
| 2025-06-24 | 270-day volume weighted average price after Subscription Agreement closing was below $850, triggering Make-Whole Provision. |
| 2025-06-30 | Veru and Company entered into a limited waiver agreement, extending Veru Notes payment to July 31, 2025; Proteomedix terminated April 2024 lease amendment and partially terminated a prior lease. |
| 2025-07-14 | Term end date for second statement of work with vendor for subscription services. |
| 2025-07-16 | Company entered into Agreement and Plan of Merger with Ocuvex Therapeutics, Inc.; Company exercised voluntary Series C Preferred Stock adjustment right to lower conversion price to $3.50. |
| 2025-07-31 | Veru and Company entered into a waiver agreement, extending Veru Notes payment to August 14, 2025. |
| 2025-08-06 | Company issued a subordinated promissory note to Keystone Capital Partners, LLC, maturing March 6, 2026. |
| 2025-08-07 | Veru and Company amended and restated September Veru Note, increasing principal by $100,000 to $5.1 million and extending maturity to August 14, 2025. |
| 2025-08-14 | Veru and Company entered into a waiver agreement, extending Veru Notes payment to August 31, 2025. |
| 2025-08-15 | Company issued 2,492 restricted stock to Board members, vesting August 16, 2026. |
| 2025-08-16 | Modified vesting date for 137 shares previously issued to Board members. |
| 2025-08-28 | Company issued two subordinated promissory notes to Keystone Capital Partners, LLC, maturing May 28, 2026; Veru and Company amended and restated September Veru Note, increasing principal by $100,000 to $5.2 million and extending maturity to September 19, 2025; Veru and Company entered into a waiver agreement, extending September Veru Note payment to September 19, 2025. |
| 2025-08-31 | Extended payment date for Veru Notes. |
| 2025-09-17 | Proteomedix entered into a license agreement with Immunovia AB. |
| 2025-09-19 | Extended maturity date for September Veru Note. |
| 2025-09-22 | Company completed Series D PIPE Financing; Company and Veru entered into a Settlement Agreement and Release; Keystone Capital Partners, LLC and Company agreed to exchange principal owed under certain Keystone Notes for Series D Preferred Stock and Warrants. |
| 2025-09-24 | Ocuvex confirmed receipt of Termination Payment, Merger Agreement terminated; Veru confirmed receipt of Settlement Amounts, Veru Notes cancelled. |
| 2025-09-30 | End of quarterly period; Company's defined benefit pension plan fully terminated and settled. |
| 2025-10-01 | Company entered into Series E Securities Purchase Agreement. |
| 2025-11-10 | Company's cash balance was approximately $6.1 million. |
| 2025-11-12 | Date of 10-Q filing; Maturity date of February Keystone Note. |
| 2025-11-17 | Last payment due for insurance financing note payable. |
| 2026-01-01 | Immunovia AB royalty payments on net sales begin. |
| 2026-03-06 | Maturity date of August 6 Keystone Note. |
| 2026-08-16 | Vesting date for 2,492 restricted stock issued to Board members. |
| 2032-12-31 | Immunovia AB royalty payments on net sales end. |
| 2038 | LabCorp license agreement and royalty payment provisions expire. |
Recommendation
strong sellThe company faces severe financial instability, explicitly stating 'substantial doubt about its ability to continue as a going concern.' Despite recent capital raises, the cash position remains precarious relative to ongoing losses and liabilities. Revenue has plummeted by over 70%, and a key product (ENTADFI) has been abandoned. The presence of material weaknesses in internal controls indicates significant operational and financial reporting risks. While cost-cutting and debt restructuring have occurred, these are reactive measures to a deteriorating situation. The repeated reverse stock splits and continuous need for dilutive financing suggest a company struggling for survival, making it a highly speculative and high-risk investment with significant downside potential for common stockholders.
Keywords
Onconetix, ONCO, Biotechnology, Proclarix, Prostate Cancer Diagnostic, SEC Filing, 10-Q, Financial Results, Going Concern, Capital Raise, Debt Restructuring, Biomarker, Diagnostics, Healthcare, Corporate Governance, Internal Controls
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.